SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, an EssilorLuxottica company and one of the world’s leading over-the-counter eyewear brands, has announced a new licensing partnership with international denim brand Wrangler. Inspired by rodeo fashi…
Author: Business Wire
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April…
PRISM Vision Group Continues to Enhance Eye Care Through Retina Macula Institute Partnership
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–PRISM Vision Group announced that it closed a transaction with Retina Macula Institute, through which RMI joins its network of affiliated practices.
National Vision Holdings, Inc. Reports First Quarter 2026 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)– #nationalvision–National Vision, Inc. (NASDAQ: EYE), one of the largest optical retailers in the United States, today reported its first quarter 2026 results.
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical condit…
NeuroVision Acquires Durin Life Sciences to Advance Earlier Detection and Management of Neurodegenerative Disease
SACRAMENTO, Calif.–(BUSINESS WIRE)–NeuroVision Imaging acquires Durin Life Sciences to build a platform for earlier neurodegenerative disease detection and care.
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that …
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Bruno Vision Care vince il premio 2026 MedTech Breakthrough
BOCA RATON, Fla.–(BUSINESS WIRE)–Cataltheia Group e la sua controllata statunitense, Bruno Vision Care LLC, azienda leader nell’innovazione della salute degli occhi, oggi hanno annunciato che la loro tecnologia di lente a contatto monouso giornaliera…
Asset Value Investors (AVI)呼籲Rohto Pharmaceutical專注核心業務，並與股東進行更具建設性的溝通
倫敦–(BUSINESS WIRE)–(美國商業資訊)– Asset Value Investors Limited (「AVI」)今日宣布，就其針對Rohto Pharmaceutical Co., Ltd. (TSE：4527，「Rohto」)的公開倡議發佈最新進展。此行動為去年發起、旨在提升該公司企業價值的持續性倡議「Awakening Rohto」之後續。AVI已在專屬網站(www.AwakeningRohto.com)上發布了詳細的簡報。 自2024年6月開始投資以來，AVI一直試圖…
Bruno Vision Care Wins 2026 MedTech Breakthrough Award
BOCA RATON, Fla.–(BUSINESS WIRE)– #ContactLenses–Bruno Vision Care’s FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award.
Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders
LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (“AVI”) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, “Rohto”), as a follow-up to its ongoing campaign, “Awakening Rohto”, launched last year…
New Sharper Image x Foster Grant Collection Brings Tech to Your Temples
SMITHFIELD, R.I.–(BUSINESS WIRE)–Foster Grant, one of the world’s leading over-the-counter eyewear brands, has partnered with Sharper Image, an iconic brand known for merging innovative designs into everyday use items, to create a range of feature-ri…
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy…
Warby Parker Announces First Quarter 2026 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2026. Highlights Delive…
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for Research in …
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing …
Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #ASGCT–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today a…
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that pro…
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
BERLIN & SAN FRANCISCO–(BUSINESS WIRE)–Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of …